- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04274426
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA)
A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967
Study Overview
Status
Detailed Description
136 patients will be randomized into the follow-ing two treatment arms as specified below:
Arm A: Control arm Platinum-based chemotherapy Arm B: Carboplatin + Mirvetuximab soravtansine (IMGN853)
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Anja Krueger
- Phone Number: 30 +49 611 880467
- Email: akrueger@ago-ovar.de
Study Contact Backup
- Name: Gabriele Elser
- Phone Number: +49611880467
- Email: gelser@ago-ovar.de
Study Locations
-
-
-
Berlin, Germany
- Recruiting
- Charite Campus Virchow Klinikum
-
Contact:
- Jalid Sehouli
-
Dessau, Germany
- Recruiting
- Städtische Klinikum Dessau
-
Contact:
- Maria Ganser
-
Dresden, Germany
- Recruiting
- Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden
-
Contact:
- Pauline Wimberger
-
Düsseldorf, Germany
- Not yet recruiting
- Universitatsklinikum Dusseldorf
-
Contact:
- Tanja Fehm
-
Essen, Germany
- Recruiting
- Evangelische Kliniken-Essen-Mitte
-
Contact:
- Philipp Harter
-
Frankfurt, Germany
- Recruiting
- Universitätsklinikum Frankfurt
-
Contact:
- Sebastian Wagner
-
Hamburg, Germany
- Recruiting
- Universitatsklinikum Hamburg Eppendorf
-
Contact:
- Barbara Schmalfeldt, Prof.
-
Hannover, Germany
- Recruiting
- Medizinische Hochschule Hannover
-
Contact:
- Tjoung-Won Park-Simon
-
Karlsruhe, Germany
- Recruiting
- ViDia Christliche Kliniken Karlsruhe
-
Contact:
- Oliver Tome, Dr. med.
-
Krefeld, Germany
- Recruiting
- Helios Klinikum Krefeld
-
Contact:
- Gunther Rogmans
-
Köln-Hohenlind, Germany
- Recruiting
- St. Elisabeth-Krankenhaus GmbH
-
Contact:
- Daniel Rein
-
Mannheim, Germany
- Recruiting
- Klinikum Mannheim
-
Contact:
- Frederik Marmé
-
Marburg, Germany
- Not yet recruiting
- OnkoNet Marburg
-
Contact:
- Christina Balser, Dr. med.
-
München, Germany
- Recruiting
- Klinikum der Universität München
-
Contact:
- Fabian Trillsch
-
München, Germany
- Recruiting
- Rotkreuzklinikum Munchen
-
Contact:
- Martin Poelcher
-
München, Germany
- Recruiting
- TU München, Klinikum recht der Isar
-
Contact:
- Holger Bronger
-
Münster, Germany
- Recruiting
- Universitätsklinik Münster
-
Contact:
- Ralf Witteler
-
Rostock, Germany
- Recruiting
- Klinikum Südstadt Rostock
-
Contact:
- Christian George, Dr. med.
-
Ulm, Germany
- Recruiting
- Universitätsfrauenklinik Ulm
-
Contact:
- Fabienne Schochter
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients must have a pathologically documented, definite diagnosis of epithelial cancer of the ovary, the fallopian tube or the peritoneum
- Relapsed disease with a platinum-free interval >3 months
- All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed Mullerian tumors, MMMT)
- Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation in germline or somatic testing if they underwent PARP inhibitor therapy in previous treatment line.
Patients must be willing to provide archival tumor tissue from current relapse or previous surgeries/biopsies for central confirmation of FRα high status by PS2+ scoring:
all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+ intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.
- Patients must have measurable disease or evaluable disease in combination with GCIG CA-125 criteria.
- Patients had one or more prior lines of chemotherapy. The last line of chemotherapy should have included platinum and has resulted in a partial or complete response.
- Major surgery (not including placement of vascular access device, tumor punch/scrape biopsies or secondary wound closure) must be completed four weeks prior to Day 1.
Patients must have adequate hematological, liver, cardiac and kidney function:
- Hemoglobin ≥ 10.0 g/dL.
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L.
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
- Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.
- Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate of at least 40 ml/minute according to Cockroft-Gault formula.
- Patient is female and ≥18 years of age at the time of the first screening visit.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements.
Women of childbearing potential (a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently ster-ile. Permanent sterilization methods include hysterectomy, bi-lateral salpingectomy and bilateral oophorectomy) must have a negative serum pregnancy test within 3 days from day 1 of cycle 1 and agree to use a highly effective method of contraception while on study treatment and for at least 6 months after end of treatment. Such methods include:
Combined (estrogen and progestogen containing) hor-monal contraception associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
Progestogen-only hormonal contraception associated with inhibition of ovulation:
- oral
- injectable
- implantable
- Intrauterine device (IUD)
- Intrauterine hormone-releasing system ( IUS)
- Bilateral tubal occlusion
- Vasectomized partner
- Sexual abstinence
Exclusion Criteria:
- Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors)
- Ovarian tumors of low malignant potential (e.g. borderline tumors).
- Unknown BRCA status.
- Patients who are planned to receive bevacizumab for the current relapse.
- Other malignancy within the last 3 years (except cervix or breast in situ carcinoma, type I stage I endometrial cancer)
- Patients who underwent surgery for the current relapse with macroscopic complete resection
- Prior systemic anticancer therapy within 28 days before randomization
- Prior treatment with folate receptor-targeting investigational agents is not allowed.
- Patients with > Grade 1 peripheral neuropathy.
- Serious concurrent illness or clinically-relevant active infection
- Previous clinical diagnosis of non-infectious interstitial lung disease, including non-infectious pneumonitis.
- Active or chronic corneal disorders such as Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision. Active or chronic corneal disorder
- Required use of folate-containing supplements (e.g. folate deficiency)
- Women of childbearing potential (WOCBP) not protected by highly effective contraceptive methods.
- Pregnant and/or breast-feeding women.
- Known hypersensitivity to one of the chemotherapy re-gimes and/or PARP inhibitors and/or any of their excipients.
- Patients with prior hypersensitivity to monoclonal antibodies.
- Patients with potential risks according to contraindication, warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for partici-pation in this trial.
- Patients with untreated or symptomatic central nervous system (CNS) metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control arm with Platinum-based chemotherapy
|
Carboplatin will administered by intravenous route
PLD will be administered by intravenous route
Gemcitabine will be administered by intravenous route
Paclitaxel will be administered by intravenous route
|
Experimental: Carboplatin + Mirvetuximab soravtansine (IMGN853)
Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
|
Carboplatin will administered by intravenous route
Mirvetuximab Soravtansine will be administered by intravenous route
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assess-ment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Time Frame: Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.
|
PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
|
Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: Up to 2.5 years. From date of randomization until date of death from any cause.
|
Overall survival
|
Up to 2.5 years. From date of randomization until date of death from any cause.
|
ORR
Time Frame: Up to 2.5 years. From date of randomization to date of death death from any cause.
|
Objective response rate
|
Up to 2.5 years. From date of randomization to date of death death from any cause.
|
Efficacy regarding PFS
Time Frame: Up to 2.5 years. From date of randomization to date of death from any cause.
|
Efficacy regarding Progression Free Survival depending on histologic subtype
|
Up to 2.5 years. From date of randomization to date of death from any cause.
|
Efficacy regarding OS
Time Frame: Up to 2.5 years. From date of randomization to date of death from any cause.
|
Efficacy regarding Overall Survival depending on histologic subtype
|
Up to 2.5 years. From date of randomization to date of death from any cause.
|
Efficacy regarding ORR
Time Frame: Up to 2.5 years. From date of randomization to date of death from any cause.
|
Efficacy regarding Objective Response Rate depending on histologic subtype
|
Up to 2.5 years. From date of randomization to date of death from any cause.
|
Serological progressive disease
Time Frame: Up to 2.5 years. From date of randomization to date of death death from any cause.
|
Time to serological progressive disease according to GCIG criteria
|
Up to 2.5 years. From date of randomization to date of death death from any cause.
|
Time to first subsequent treatment (TFST)
Time Frame: Up to 2.5 years. From date of randomization to date of death from any cause.
|
Time to first subsequent treatment (TFST)
|
Up to 2.5 years. From date of randomization to date of death from any cause.
|
Time to second subsequent treatment (TSST)
Time Frame: Up to 2.5 years. From date of randomization until date of death from any cause.
|
Time to second subsequent treatment (TSST)
|
Up to 2.5 years. From date of randomization until date of death from any cause.
|
Patient-reported outcomes
Time Frame: Up to 2.5 years. From date of randomization until date of death from any cause.
|
Quality of Life (EORTC C-30)
|
Up to 2.5 years. From date of randomization until date of death from any cause.
|
Patient-reported outcomes
Time Frame: Up to 2.5 years. From date of randomization until date of death from any cause.
|
Quality of Life (EORTC OV28)
|
Up to 2.5 years. From date of randomization until date of death from any cause.
|
Safety and tolerability
Time Frame: Up to 2.5 years. From date of randomization until date of death from any cause through study completion.
|
Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0
|
Up to 2.5 years. From date of randomization until date of death from any cause through study completion.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Philipp Harter, Kliniken Essen-Mitte, Germany
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Recurrence
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Immunoconjugates
- Carboplatin
- Paclitaxel
- Doxorubicin
- Liposomal doxorubicin
- Maytansine
- Gemcitabine
- Mirvetuximab soravtansine
Other Study ID Numbers
- AGO-OVAR 2.34
- 2018-004207-39 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditionsCanada
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Sanofi Pasteur, a Sanofi CompanyCompletedStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditionsUnited States
-
Ira WinerRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
-
Northwestern UniversityNational Comprehensive Cancer NetworkCompletedRecurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Primary Peritoneal CancerUnited States
-
Roswell Park Cancer InstituteActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland